摘要
目的探讨孟鲁司特钠联合地氯雷他定治疗小儿过敏性紫癜的临床疗效及安全性。方法选取江苏大学附属宜兴市人民医院儿科2014年1月—2016年1月收治的过敏性紫癜患儿80例,根据随机数字表法分为对照组和治疗组,各40例。对照组患儿给予常规治疗,治疗组患儿在对照组基础上给予孟鲁司特钠联合地氯雷他定治疗,比较两组患儿的临床疗效及皮疹、消化道症状、关节症状消失时间、住院时间,并观察患儿不良反应发生情况。结果治疗组患儿治疗总有效率高于对照组(P<0.05)。治疗组患儿皮疹、消化道症状、关节症状消失时间及住院时间短于对照组(P<0.05),两组患儿均未出现严重不良反应。结论采用孟鲁司特钠联合地氯雷他定治疗小儿过敏性紫癜的临床疗效确切,可有效改善患儿的临床症状,缩短住院时间,且安全性高。
Objective To investigate the clinical effect and the safety of montelukast sodium combined with desloratadine in treating childhood henoch-schonlein purpura.Methods A total of 80 cases of childern with henoch-schonlein purpura were selected from January 2014 to January 2016 in Department of Pediatrics of Yixing People＆#39;s Hospital Affiliated to Jiangsu University,which were divided into control group and treatment group according to random numbers table method,40 cases in each group.Control group was given conventional treatment,treatment group was given montelukast sodium combined with desloratadine based on control group.The clinical effect,disappear time of rash,digestive symptoms,arthritis symptom and hospital stays,and the incidence of adverse reactions were compared between the two groups.Results The treatment group of clinical effect was better than control group（P〈0.05）.The disappear time of rash,digestive symptoms,arthritis symptom and hospital stays of treatment group were shorter than control group（P〈0.05）.There was no serious adverse reactions was happened.Conclusion The montelukast sodium combined with desloratadine have an exactly clinical effect in treating childhood henoch-schonlein purpura,it can effectively improve the clinical symptoms,shorten hospital stays,and with high safety.
出处
《临床合理用药杂志》
2017年第15期14-15,共2页
Chinese Journal of Clinical Rational Drug Use
关键词
紫癜
过敏性
孟鲁司特钠
地氯雷他定
治疗结果
Purpura,schoenlein-henoch
Montelukast sodium
Desloratadine
Treatment outcome
